Despite FDA Recommendation for Postmarketing Surveillance, Amgen's Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis

Friday, January 8, 2010 Medical PDA News
Email Print This Page Comment bookmark
Font : A-A+

Prolia's Uptake Will Likely be Tempered Until Long-Term Safety is Verified, According to New Findings from Decision Resources

Decision Resources

Decision Resources, Inc.

Christopher Comfort

Elizabeth Marshall

781-296-2597

781-296-2563

ccomfort@dresources.com

emarshall@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook